Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating CYB003, a deuterated psilocin analog, as an additional treatment for adults with Major Depressive Disorder MDD. This Phase III study aims to assess the effectiveness, safety, and tolerability of two different doses of CYB003 compared to a placebo in people who continue their current antidepressant medication. The study is randomized, double-blind, and involves multiple centers. Participants are assigned to one of three groups two experimental arms receiving either 8 mg or 16 mg of CYB003 during two medicine sessions spaced about three weeks apart, or a placebo arm receiving placebo sessions on the same schedule. Throughout the trial, all participants maintain their current antidepressants and receive psychological support. Non-responders to placebo may join a later extension trial to receive CYB003. During the trial, participants undergo evaluations using several scales that assess depression severity, anxiety, global clinical impression, and quality of life at multiple time points from screening through up to 84 days or end of trial. Psychological support sessions and dosing visits are conducted, and safety is monitored. The total study participation lasts approximately three months, with detailed assessments scheduled at baseline and various days post-treatment.
Actively Recruiting
Major depressive disorder MDD is a mood disorder causing ongoing sadness and loss of interest, with emotional and physical symptoms such as irritability, difficulty focusing, tiredness, and changes in eating habits. Researchers are studying oral Icalcaprant, an investigational drug, to assess its effects on disease activity and side effects in adults currently experiencing a major depressive episode. Participants are randomly assigned to one of three groups two different doses of Icalcaprant or a placebo. They will take oral capsules once daily for 6 weeks, followed by a 30-day safety follow-up period. The study is conducted at about 35 sites across North America and involves approximately 195 adults. During the study, participants will attend regular visits at a hospital or clinic where medical assessments, blood tests, side effect checks, and questionnaires will be completed. Researchers will measure changes in depression severity using scales like the Montgomery-sberg Depression Rating Scale MADRS over about 6 weeks, and adverse events will be monitored for up to 10 weeks total.
Actively Recruiting
Researchers are evaluating the antidepressant effects of ALTO-100 compared to a placebo in adults with Bipolar Disorder I or II who are currently experiencing a major depressive episode. This study aims to understand how patient characteristics may influence treatment outcomes when ALTO-100 is used along with a mood stabilizer andor an atypical antipsychotic. The trial also focuses on assessing safety, tolerability, and efficacy during a later open-label treatment phase. Participants in the study will be randomly assigned to receive either ALTO-100 at a dose of 40 mg twice daily or a matching placebo for 6 weeks during the double-blind treatment period. Those who qualify and continue will enter an open-label period lasting up to 7 weeks, where all will receive ALTO-100 40 mg twice daily. The study uses a quadruple-blind design to ensure unbiased results. During the trial, participants will undergo regular assessments of depression symptoms using scales such as the Montgomery-sberg Depression Rating Scale MADRS, Patient Health Questionnaire PHQ-9, and Clinician Global Impression Scale-severity CGI-S. Safety monitoring includes tracking adverse events, heart rate, blood pressure, weight, and suicidality over a total period of up to 13 weeks. The study evaluates changes from baseline to week 6 during the double-blind phase and continues safety assessments through the open-label period.
Actively Recruiting
Researchers are conducting a Phase 2 study to find the appropriate dose of CK-4021586 in adults aged 40 to 85 with symptomatic heart failure with preserved ejection fraction HFpEF. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this drug in people with this condition, which involves heart failure while maintaining a normal ejection fraction. The trial is randomized, double-blind, and placebo-controlled to provide reliable results. Participants may receive different daily doses of CK-4021586 150 mg, 300 mg, 450 mg, or 600 mg for up to 12 weeks, with dosing guided by echocardiography assessments. There are several study groups, including placebo groups, to compare the effects of the drug. The dose levels are organized in cohorts, with participants assigned randomly to receive either the drug or placebo over the 12-week treatment period. During the study, participants will undergo regular evaluations including echocardiography to monitor left ventricular ejection fraction LVEF and blood tests for NT-proBNP levels, a marker of heart failure. The researchers will assess drug safety by tracking adverse events and early discontinuation rates. Blood samples will also be taken to measure drug concentrations and how these relate to changes in heart function. Total participation lasts for 12 weeks, during which participants have scheduled visits for monitoring and assessments.
Actively Recruiting
Evaluation of TSND-201 Capsules Versus Placebo for Treating Post Traumatic Stress Disorder in Adults
Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.
Actively Recruiting
Researchers are studying the effects of solriamfetol in adults with major depressive disorder MDD who also experience excessive daytime sleepiness EDS. This Phase 3 trial involves an open-label treatment phase followed by a randomized, double-blind withdrawal phase. The goal is to evaluate the time to relapse of depressive symptoms when continuing solriamfetol versus switching to placebo. Participants first undergo a screening period and then receive open-label solriamfetol tablets once daily. Those who respond to treatment enter a double-blind phase where they are randomly assigned to either continue solriamfetol 150 mg daily or switch to a placebo. This withdrawal period lasts up to 24 weeks or until depressive symptoms relapse. Throughout the study, participants are monitored for clinical response and relapse of symptoms. The primary outcome is the time from randomization to relapse of depressive symptoms. The study includes follow-up to assess ongoing symptoms, with a total participation duration that includes screening, treatment, randomized withdrawal, and follow-up periods.
Actively Recruiting
Researchers are studying the effects and safety of SPN-812 viloxazine extended release in children aged 4 to 5 years who have Attention-DeficitHyperactivity Disorder ADHD. This study is a Phase 4, randomized, double-blind, placebo-controlled trial designed to compare SPN-812 with a placebo in preschool-age children diagnosed with ADHD. The goal is to evaluate how well the medication works and how tolerable it is in this young population. Participants will be randomly assigned to receive either 100mg SPN-812 or a placebo once daily for a 6-week treatment period. Before starting treatment, children will be screened for up to 4 weeks to determine eligibility. The total study duration for each participant is up to 10 weeks, including screening and treatment. This design allows researchers to compare the effects of SPN-812 against placebo over a set timeframe. During the study, participants will be evaluated using the ADHD Rating Scale, 4th Edition, Preschool Version ADHD-RS-IV-P to measure changes in ADHD symptoms. Other assessments include the Clinical Global Impression of Severity and Change scores. Parents or guardians will provide consent, and children will be regularly monitored for safety and treatment response. Researchers will collect data at baseline and at the end of the 6-week treatment period to assess the medications impact and any side effects.
Actively Recruiting
Researchers are conducting a pre-screening study to identify individuals who may qualify for Roche interventional studies focused on Alzheimers disease. This study aims to assess potential eligibility by evaluating specific biomarkers and cognitive performance, helping to select suitable participants for future clinical trials related to Alzheimers disease. Participants will undergo testing to measure the concentration of pTau217 in their blood and complete the International Shopping List Test ISLT to assess cognitive function. There is no active treatment or intervention instead, the study collects these measurements to determine potential trial eligibility. During the study, participants will have blood samples drawn and complete cognitive assessments using the ISLT. Researchers will focus on the pTau217 biomarker levels and cognitive scores as primary outcomes measured on the first day of participation. This screening process helps identify candidates for subsequent interventional Alzheimers disease trials. The study is planned to run until July 2035 and includes adults aged 50 to 90 years.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of ITI-1284 as an additional treatment for adults with Generalized Anxiety Disorder GAD who have not had sufficient improvement from their current GAD medication. This study is a multicenter, randomized, double-blind, placebo-controlled trial focusing on patients diagnosed with moderate to severe GAD according to the DSM-5-TR criteria. Participants are randomly assigned to one of three groups to receive either ITI-1284 10 mg, ITI-1284 20 mg, or a matching placebo. All treatments are administered as once-daily sublingual tablets alongside their ongoing GAD therapy. The study treatment period lasts for six weeks, during which participants continue their existing GAD medication at stable doses. Throughout the study, participants will undergo assessments including the Hamilton Anxiety Rating Scale HAM-A and the Clinical Global Impression Scale-Severity CGI-S to measure anxiety symptoms and overall severity. The primary outcome is measured at week 6. Safety and tolerability are monitored closely during visits. The total duration of participation aligns with the six-week treatment period.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of ABBV-932 when added to antidepressant therapies ADTs in adults with generalized anxiety disorder GAD who have not adequately responded to ADTs alone. The study is a Phase 2, randomized, double-blind, placebo-controlled trial involving approximately 315 adult participants across about 50 sites in the United States and Puerto Rico. ABBV-932 is an investigational oral drug developed as an adjunct treatment for GAD. Participants will be randomly assigned to one of three groups two different doses of ABBV-932 added to their prescribed ADTs, or a placebo added to their ADTs. The treatment period lasts for 6 weeks, during which participants will take oral capsules of ABBV-932 or placebo alongside their ongoing antidepressant treatment. Following the treatment, there is a 4-week follow-up period to monitor outcomes and safety. During the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted to evaluate the treatments impact. The main outcomes measured include the number of adverse events and changes in anxiety levels assessed by the Hamilton Anxiety Scale. Additional assessments include worry questionnaires and depression rating scales. The total participation time is approximately 10 weeks, covering treatment and follow-up.
1-10 of 11
1